Busulfanum

Li-Fraumeni Syndrome

Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

17 Active assets in the Li-Fraumeni Syndrome cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Masonic Cancer Center, University of Minnesota	Phase 2	B
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Masonic Cancer Center, University of Minnesota	Phase 2	CCC
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine) The First Affiliated Hospital with Nanjing Medical University	Phase 2	CCC
Catequentinib Tianjin Medical University Cancer Institute and Hospital	Phase 2	CCC
Fludarabine Masonic Cancer Center, University of Minnesota	Phase 2	CCC